Update on Statin Use in Pregnancy

Poornima, Indu; Pulipati, Vishnu Priya; Brinton, Eliot A.; Wild, Robert A.

doi:10.1016/j.amjmed.2022.08.029

Cited by 9 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An important highlight over the usage of statins in pregnancy is the withdrawal of their contraindication in pregnancy by the FDA for pregnant women or for those considering pregnancy. As it became evident from a number of studies investigating the safety of statins, the rate of miscarriages, congenital disturbances, median gestational age at birth or weight at birth did not show significant increases with no reports on teratogenic effects in the first trimester, though preterm birth was noted more frequently 28 . It is of interest to be mentioned that adverse events in pregnancy were noted more commonly with lipophilic statins than with hydrophilic probably due to their potential passage through the placenta 29 .…”

Section: Statinsmentioning

confidence: 98%

A narrative review of treatment modalities for familial hypercholesterolemia

Samprokatsidis,

Antza,

Frangou

et al. 2023

JAPT

View full text Add to dashboard Cite

Familial Hypercholesterolemia (FH), a commonly missed disorder in a patient with abnormalities in lipid metabolism is described as a heritable disorder presenting elevated LDL cholesterol and lipid deposition in various tissues. This contributes to the early development of manifestations of atherosclerotic disease with the preterm occurrence of severe cardiovascular events. Apparently, decision-making is a strenuous effort and many individuals are underdiagnosed. FH affects LDL receptor and its function plays a critical role in the mechanism of many therapeutic modalities, thus alternative pathways must also be considered. This review addresses the main options of care in individuals with familial hypercholesterolemia along with unconventional drugs like mipomersen, inclisiran, lomitapide, gamcabene, and ANGLT3 inhibitors which have yielded important results for disease management.

show abstract

Section: Statinsmentioning

confidence: 98%

A narrative review of treatment modalities for familial hypercholesterolemia

Samprokatsidis,

Antza,

Frangou

et al. 2023

JAPT

View full text Add to dashboard Cite

show abstract

“…Additionally, statin treatment has been found to impair gestational outcomes [88,89]. However, these initial concerns were not confirmed in recent animal and clinical trials, and in July 2021, the FDA allowed the use of statins during pregnancy but only in certain cases: among women with familiar hypercholesterolemia, those suffering from severed LDL cholesterol level, those with cardiovascular diseases, or in cases where the benefits are judged to outweigh any risk [90].…”

Section: Statins-the Old Friends Of the Cardiovascular System Offerin...mentioning

confidence: 99%

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Sakowicz

Bralewska

Rybak-Krzyszkowska

et al. 2023

IJMS

View full text Add to dashboard Cite

Preeclampsia (PE) is a pregnancy-specific disorder affecting 4–10% of all expectant women. It greatly increases the risk of maternal and foetal death. Although the main symptoms generally appear after week 20 of gestation, scientific studies indicate that the mechanism underpinning PE is initiated at the beginning of gestation. It is known that the pathomechanism of preeclampsia is strongly related to inflammation and oxidative stress, which influence placentation and provoke endothelial dysfunction in the mother. However, as of yet, no “key players” regulating all these processes have been discovered. This might be why current therapeutic strategies intended for prevention or treatment are not fully effective, and the only effective method to stop the disease is the premature induction of delivery, mostly by caesarean section. Therefore, there is a need for further research into new pharmacological strategies for the treatment and prevention of preeclampsia. This review presents new preventive methods and therapies for PE not yet recommended by obstetrical and gynaecological societies. As many of these therapies are in preclinical studies or under evaluation in clinical trials, this paper reports the molecular targets of the tested agents or methods.

show abstract

“…The FDA requested the elimination of the longstanding restriction on employing statins in women who are pregnant or planning to become pregnant. This modification holds particular significance for healthcare practitioners tending to women of a reproductive age who have familial hypercholesterolemia or a background of atherosclerotic cardiovascular conditions [ 97 ].…”

Section: The Usage Of Statins In Preeclampsiamentioning

confidence: 99%

Recent Advances in the Prevention and Screening of Preeclampsia

Mészáros,

Kukor,

Valent

2023

JCM

View full text Add to dashboard Cite

Throughout the history of medicine, preeclampsia has remained an enigmatic field of obstetrics. In 2023, despite its prevalence and impact, preeclampsia’s exact cause and effective treatment remain elusive; the current options are limited to delivery. The purpose of this review is to summarize the knowledge of the possible novel prophylactic therapies and screening methods for preeclampsia, thereby providing valuable insights for healthcare professionals and researchers. Aspirin and LMWH have already been widely used; meanwhile, calcium, vitamin D, and pravastatin show promise, and endothelin receptor antagonists are being explored. Stress reduction, dietary changes, and lifestyle modifications are also being investigated. Another interesting and fast-growing area is AI- and software-based screening methods. It is also key to find novel biomarkers, which, in some cases, are not only able to predict the development of the disease, but some of them hold promise to be a potential therapeutic target. We conclude that, while a definitive cure for preeclampsia may not be eligible in the near future, it is likely that the assessment and enhancement of preventive methods will lead to the prevention of many cases. However, it is also important to highlight that more additional research is needed in the future to clarify the exact pathophysiology of preeclampsia and to thus identify potential therapeutic targets for more improved treatment methods.

show abstract

Update on Statin Use in Pregnancy

Cited by 9 publications

References 18 publications

A narrative review of treatment modalities for familial hypercholesterolemia

A narrative review of treatment modalities for familial hypercholesterolemia

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Recent Advances in the Prevention and Screening of Preeclampsia

Contact Info

Product

Resources

About